Both Coherus BioSciences Inc. (NASDAQ:CHRS) and Principia Biopharma Inc. (NASDAQ:PRNB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coherus BioSciences Inc.||37.10M||32.27||185.05M||-3.11||0.00|
|Principia Biopharma Inc.||62.85M||12.06||8.77M||0.21||151.31|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Coherus BioSciences Inc. and Principia Biopharma Inc.
Table 2 shows the return on assets, net margins and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Coherus BioSciences Inc.||-498.79%||0%||-120.3%|
|Principia Biopharma Inc.||-13.95%||0%||0%|
3.8 and 3.8 are the respective Current Ratio and a Quick Ratio of Coherus BioSciences Inc. Its rival Principia Biopharma Inc.’s Current and Quick Ratios are 10.7 and 10.7 respectively. Principia Biopharma Inc. has a better chance of clearing its pay short and long-term debts than Coherus BioSciences Inc.
The following table delivered below contains the ratings and recommendations for Coherus BioSciences Inc. and Principia Biopharma Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Coherus BioSciences Inc.||0||0||2||3.00|
|Principia Biopharma Inc.||0||0||1||3.00|
The consensus target price of Coherus BioSciences Inc. is $25, with potential upside of 44.84%. Meanwhile, Principia Biopharma Inc.’s consensus target price is $45, while its potential upside is 41.64%. The information presented earlier suggests that Coherus BioSciences Inc. looks more robust than Principia Biopharma Inc. as far as analyst opinion.
Institutional and Insider Ownership
The shares of both Coherus BioSciences Inc. and Principia Biopharma Inc. are owned by institutional investors at 99.1% and 95.7% respectively. Insiders owned roughly 0.3% of Coherus BioSciences Inc.’s shares. Comparatively, 13.92% are Principia Biopharma Inc.’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Coherus BioSciences Inc.||6.64%||15.6%||20.46%||70.96%||2.63%||89.94%|
|Principia Biopharma Inc.||4.42%||12.08%||8%||31.52%||0%||13.8%|
For the past year Coherus BioSciences Inc. has stronger performance than Principia Biopharma Inc.
On 8 of the 11 factors Principia Biopharma Inc. beats Coherus BioSciences Inc.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.